This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Iwamoto, T.
Right arrow Articles by Sonobe, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Iwamoto, T.
Right arrow Articles by Sonobe, T.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2004, p. 4023-4026, Vol. 48, No. 10
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.10.4023-4026.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Peptide Nucleic Acid-Mediated Competitive PCR Clamping for Detection of Rifampin-Resistant Mycobacterium tuberculosis

Tomotada Iwamoto* and Toshiaki Sonobe

Department of Microbiology, Kobe Institute of Health, Chuo-ku, Kobe, Japan

Received 11 February 2004/ Returned for modification 28 April 2004/ Accepted 27 May 2004


arrow
ABSTRACT
 
Peptide nucleic acid-mediated competitive PCR clamping, which can selectively amplify mutant alleles, was developed to detect mutations in four codons (513, 516, 526, and 531) of the rpoB gene in Mycobacterium tuberculosis strains. This simple method successfully identified the mutations in all 40 of the M. tuberculosis strains tested.


arrow
TEXT
 
The emergence of and increase in multidrug-resistant tuberculosis are serious threats to public health. A variety of genotypic methods that can detect the mutations in a 68-bp rifampin resistance-determining region in the rpoB gene (13-15, 17) have been reported for the rapid diagnosis of Rifr Mycobacterium tuberculosis (4-9, 11, 18-20). These tests could have tremendous potential; however, it should be noted that their predictive values would be compromised when drug-resistant organisms are present as subpopulations among predominantly susceptible tubercle bacilli (1, 4, 16). If the subpopulation exceeds 1% of the total when tested against rifampin, successful therapeutic treatment of the patient may be compromised (3).

Here we describe the development of a peptide nucleic acid (PNA)-mediated competitive PCR clamping (PMCPC) technique for the detection of mutations in the rifampin resistance-determining region. An outline of this assay is depicted in Table 1. Because PCR clamping was done with wild-type complementary PNA probes, the mutant allele was selectively amplified and could easily be characterized by the presence of amplicon 1. The performance of the assay was evaluated for specificity, sensitivity, and subpopulation detection.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Schematic view of rpoB gene fragment targeted by PMCPC assaysa

Forty M. tuberculosis strains (wild type, 16 strains; 531TTG mutant, 12 strains; 531TGG mutant, 2 strains; 526CGC mutant, 4 strains; 526TAC mutant, 2 strains; 526GAC mutant, 1 strain; 526GGC mutant, 1 strain; 516TAC mutant, 1 strain; 513CGA mutant, 1 strain) were used for evaluation of the PMCPC assay. Two outer primers (OPF [12] and OPR) and one inner primer (IPF), together with one of the wild-type allele-specific PNA probes, were used for the PMCPC assays (Table 2). The interpretation of the results is summarized in Table 1. The PCR mixture (final volume of 50 µl) consisted of genomic DNA (1 ng) and 10x buffer with 15 mM MgCl2, 200 µM each deoxynucleoside triphosphate, enzyme mix (0.6 µl) (Expand high-fidelity PCR system; Roche Diagnostics GmbH), 20 pmol each of the OPF, OPR, and IPF primers, and 100 pmol of an allele-specific PNA probe. PMCPC reactions were performed with a GeneAmp PCR System 9700 (Applied Biosystems Japan Ltd., Tokyo, Japan) under the following conditions: initial denaturation at 95°C for 3 min; 45 cycles of 94°C for 30 s (denaturation), 67°C for 30 s (PNA hybridization), and 60°C for 30 s (primer annealing and extension); and a final elongation at 72°C for 7 min. The amplified fragments were detected by ethidium bromide staining of agarose gels. Mixtures of mutant and wild-type target DNAs containing 50, 20, 10, 4, 2, or 1% mutant DNA were prepared and used for subpopulation analysis by PMCPC (see Fig. 2).


View this table:
[in this window]
[in a new window]
  		TABLE 2. Primers and probes used in this study



View larger version (80K):
[in this window]
[in a new window]
  		FIG. 2. PMCPC assay of heterogeneous populations of rpoB mutant and wild-type (strain H37Rv) bacteria. Mixtures of mutant and wild-type target DNAs were as follows: 531TGG and wild-type DNAs (A), 526 TAC and wild-type DNAs (B), 516 TAC and wild-type DNAs (C), 513 CGA and wild-type DNAs (D). Mixtures of mutant and wild-type target DNAs were 50% (lane 1), 20% (lane 2), 10% (lane 3), 4% (lane 4), 2% (lane 5), and 1% (lane 6). The amount of DNA was kept at 2 ng per reaction.

The PMCPC assay successfully identified a variety of mutations in 40 M. tuberculosis strains (Fig. 1). With the addition of a PNA probe to the PCR mixture, the corresponding polymerase readthrough of the wild-type allele was hindered (absence of amplicon 1) whereas its amplification proceeded for the mutant allele (presence of amplicon 1). The 100-bp universally obtained fragments in all PCRs confirmed the success of the PCR (Fig. 1). The 517-bp fragments obtained by PCR in the absence of PNA probes indicated the presence of M. tuberculosis in the sample (Fig. 1A), where the specificity of this assay was confirmed with 20 species of nontuberculosis mycobacteria and 8 of nonmycobacteria (Table 3). The detection limit of the PMCPC assay was determined to be 100 fg of DNA (data not shown).



View larger version (39K):
[in this window]
[in a new window]
  		FIG. 1. Profiles generated by the PMCPC assay targeting four rpoB codons: codon 531 with the PNA 531 probe (B), codon 526 with the PNA 526 probe (C), and codons 516 and 513 with the PNA 513_516 probe (D). (A) PMCPC assay in the absence of PNA probes. Lanes: 1, strain H37Rv; 2 and 3, strains with rpoB 531 mutant alleles (TTG and TGG); 4 to 7, strains with rpoB 526 mutant alleles (CGC, TAC, GAC, and GGC); 8, strain with an rpoB 516 mutant allele (TAC); 9, strain with an rpoB 513 mutant allele (CGA); 10, no template DNA; M, 100-bp DNA ladder.


View this table:
[in this window]
[in a new window]
  		TABLE 3. Mycobacteria and nonmycobacteria used to determine the specificity of the PMCPC assay

It is noteworthy that complete suppression of PCR amplification of wild-type alleles could be achieved even when an excess amount of purified DNA (100 ng per reaction) was used. This proved that amplicon 1 is never obtained from wild-type alleles and there is no interference by predominantly existing wild-type DNA with the amplification of mutant allele-specific 517-bp fragments (amplicon 1). The mutant subpopulations, at a level of 2% of the total DNA in the sample, could be detected as a faint band representing amplicon 1 (Fig. 2). Sequence analysis confirmed that these faint bands were derived from the mutant and did not represent a false positive derived from an excess amount of wild-type DNA (data not shown). This potential of the PMCPC assay is favorable given that a drug-resistant subpopulation that exceeds 1% of the total is considered clinically important and represents one advantage of this assay over other genotypic methods of detecting drug-resistant M. tuberculosis. Further quantitative analysis, such as the use of densitometric data to provide physicians with more detailed information relating to the amount of mutant DNA in the wild-type DNA, would be valuable but requires more equipment and a heavier workload. Further investigations in this area are required.

The Line Probe assay (LiPA) is probably the most frequently used method at this moment (5, 7, 10). Its superiority over our assay is its ability to identify four specific mutations by R probes, which covers about 75% of the Rifr M. tuberculosis strains. However, a drawback of the LiPA is that it failed to distinguish the TTC insertion mutation at position 514 from the wild-type sequence (10). Failure to detect insertional and deletional mutations in the region covered by PNA probes is not likely to happen with the PMCPC assay since the PCR clamping can be seen only when perfectly matched sequences (wild type) exist. In addition, the LiPA cannot distinguish mutants coexisting with the wild type, which are not targeted by R probes. PMCPC has a limitation with regard to its specificity; i.e., mutations in regions other than those covered by the three PNA probes, which are estimated at about 5% of Rifr M. tuberculosis strains, fail to be detected. However, this is specific not only to the PMCPC assay but to all other molecular methods. A PNA probe costs about 50 times more than a DNA probe. The use of a PNA approach represents a rather new technology, and only a limited number of manufacturers supply PNA probes. When the use of PNA probes becomes more commonplace, it is anticipated that the associated cost will comparable to that of methods using DNA probes. Bockstahler et al. (2) first described the effectiveness of PNA probes in identifying katG and rpoB mutations in M. tuberculosis by the PNA probe hybridization-enzyme-linked immunosorbent assay method, which differs quite significantly from the approach taken in our assay.

The newly developed PMCPC technique is rapid and easy to perform with conventional PCR and agarose gel electrophoresis equipment, and the results are easy to interpret. Moreover, this assay can detect drug-resistant subpopulations with reasonable sensitivity. Our preliminary study also demonstrated the potential use of this assay for direct analysis of sputum specimens. Finally, we intend to evaluate the assay for direct analysis of clinical specimens with a large number of samples.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Department of Microbiology, Kobe Institute of Health, 4-6 Minatojima-nakamachi, Chuo-ku, Kobe 650-0046, Japan. Phone: 81-78-302-6251. Fax: 81-78-302-0894. E-mail: kx2t-iwmt{at}asahi-net.or.jp. Back


arrow
REFERENCES
 
    1
  1. Ano, H., T. Matsumoto, H. Yoshida, C. Ishida, N. Tanigawa, K. Kawahara, H. Toba, T. Takashima, and I. Tsuyuguchi. 2003. Fluctuation in the ratio between drug-resistant and -susceptible M. tuberculosis bacilli which were isolated from patients with prolonged anti-tuberculosis treatment. Kekkaku 78:739-746.[Medline]
    2. 2
  2. Bockstahler, L. E., Z. Li, N. Y. Nguyen, K. A. Van Houten, M. J. Brennan, J. J. Langone, and S. L. Morris. 2002. Peptide nucleic acid probe detection of mutations in Mycobacterium tuberculosis genes associated with drug resistance. BioTechniques 32:508-510, 512, 514.[Medline]
    3. 3
  3. Canetti, G., W. Fox, A. Khomenko, H. T. Mahler, N. K. Menon, D. A. Mitchison, N. Rist, and N. A. Smelev. 1969. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull. W. H. O. 41:21-43.[Medline]
    4. 4
  4. Cooksey, R. C., B. P. Holloway, M. C. Oldenburg, S. Listenbee, and C. W. Miller. 2000. Evaluation of the invader assay, a linear signal amplification method, for identification of mutations associated with resistance to rifampin and isoniazid in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 44:1296-1301.[Abstract/Free Full Text]
    5. 5
  5. Cooksey, R. C., G. P. Morlock, S. Glickman, and J. T. Crawford. 1997. Evaluation of a line probe assay kit for characterization of rpoB mutations in rifampin-resistant Mycobacterium tuberculosis isolates from New York City. J. Clin. Microbiol. 35:1281-1283.[Abstract]
    6. 6
  6. Cooksey, R. C., G. P. Morlock, B. P. Holloway, G. H. Mazurek, S. Abaddi, L. K. Jackson, G. S. Buzard, and J. T. Crawford. 1998. Comparison of two nonradioactive, single-strand conformation polymorphism electrophoretic methods for identification of rpoB mutations in rifampin-resistant isolates of Mycobacterium tuberculosis. Mol. Diagn. 3:73-79.[CrossRef][Medline]
    7. 7
  7. De Beenhouwer, H., Z. Lhiang, G. Jannes, W. Mijs, L. Machtelinckx, R. Rossau, H. Traore, and F. Portaels. 1995. Rapid detection of rifampicin resistance in sputum and biopsy specimens from tuberculosis patients by PCR and line probe assay. Tuberc. Lung Dis. 76:425-430.[CrossRef][Medline]
    8. 8
  8. El-Hajj, H. H., S. A. Marras, S. Tyagi, F. R. Kramer, and D. Alland. 2001. Detection of rifampin resistance in Mycobacterium tuberculosis in a single tube with molecular beacons. J. Clin. Microbiol. 39:4131-4137.[Abstract/Free Full Text]
    9. 9
  9. Felmlee, T. A., Q. Liu, A. C. Whelen, D. Williams, S. S. Sommer, and D. H. Persing. 1995. Genotypic detection of Mycobacterium tuberculosis rifampin resistance: comparison of single-strand conformation polymorphism and dideoxy fingerprinting. J. Clin. Microbiol. 33:1617-1623.[Abstract]
    10. 10
  10. Hirano, K., C. Abe, and M. Takahashi. 1999. Mutations in the rpoB gene of rifampin-resistant Mycobacterium tuberculosis strains isolated mostly in Asian countries and their rapid detection by line probe assay. J. Clin. Microbiol. 37:2663-2666.[Abstract/Free Full Text]
    11. 11
  11. Kapur, V., L. L. Li, S. Iordanescu, M. R. Hamrick, A. Wanger, B. N. Kreiswirth, and J. M. Musser. 1994. Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase beta subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas. J. Clin. Microbiol. 32:1095-1098.[Abstract/Free Full Text]
    12. 12
  12. Lee, H., H. E. Bang, G. H. Bai, and S. N. Cho. 2003. Novel polymorphic region of the rpoB gene containing Mycobacterium species-specific sequences and its use in identification of mycobacteria. J. Clin. Microbiol. 41:2213-2218.[Abstract/Free Full Text]
    13. 13
  13. Miller, L. P., J. T. Crawford, and T. M. Shinnick. 1994. The rpoB gene of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 38:805-811.[Abstract/Free Full Text]
    14. 14
  14. Musser, J. M. 1995. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin. Microbiol. Rev. 8:496-514.[Abstract]
    15. 15
  15. Ramaswamy, S., and J. M. Musser. 1998. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuberc. Lung Dis. 79:3-29.[CrossRef][Medline]
    16. 16
  16. Rinder, H., K. T. Mieskes, and T. Loscher. 2001. Heteroresistance in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 5:339-345.[Medline]
    17. 17
  17. Telenti, A., P. Imboden, F. Marchesi, D. Lowrie, S. Cole, M. J. Colston, L. Matter, K. Schopfer, and T. Bodmer. 1993. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341:647-650.[CrossRef][Medline]
    18. 18
  18. Telenti, A., P. Imboden, F. Marchesi, T. Schmidheini, and T. Bodmer. 1993. Direct, automated detection of rifampin-resistant Mycobacterium tuberculosis by polymerase chain reaction and single-strand conformation polymorphism analysis. Antimicrob. Agents Chemother. 37:2054-2058.[Abstract/Free Full Text]
    19. 19
  19. Torres, M. J., A. Criado, J. C. Palomares, and J. Aznar. 2000. Use of real-time PCR and fluorimetry for rapid detection of rifampin and isoniazid resistance-associated mutations in Mycobacterium tuberculosis. J. Clin. Microbiol. 38:3194-3199.[Abstract/Free Full Text]
    20. 20
  20. Williams, D. L., L. Spring, T. P. Gillis, M. Salfinger, and D. H. Persing. 1998. Evaluation of a polymerase chain reaction-based universal heteroduplex generator assay for direct detection of rifampin susceptibility of Mycobacterium tuberculosis from sputum specimens. Clin. Infect. Dis. 26:446-450.[Medline]

Antimicrobial Agents and Chemotherapy, October 2004, p. 4023-4026, Vol. 48, No. 10
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.10.4023-4026.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Marme, N., Friedrich, A., Muller, M., Nolte, O., Wolfrum, J., Hoheisel, J. D., Sauer, M., Knemeyer, J.-P. (2006). Identification of single-point mutations in mycobacterial 16S rRNA sequences by confocal single-molecule fluorescence spectroscopy. Nucleic Acids Res 34: e90-e90 [Abstract] [Full Text]  
  • Miotto, P., Piana, F., Penati, V., Canducci, F., Migliori, G. B., Cirillo, D. M. (2006). Use of Genotype MTBDR Assay for Molecular Detection of Rifampin and Isoniazid Resistance in Mycobacterium tuberculosis Clinical Strains Isolated in Italy.. J. Clin. Microbiol. 44: 2485-2491 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Iwamoto, T.
Right arrow Articles by Sonobe, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Iwamoto, T.
Right arrow Articles by Sonobe, T.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»